Are Gilead, Trump officials and the NIH blocking Covid-19 treatment research on GS-441524 to allow more expensive Remdesivir to proceed ?

adam

BANNED
Jul 2, 2020
183
30
730
Visit site
An open letter avialable in a PDF link further below has been sent to the FDA and Gilead by a liberal think tank and advocacy group asking ....

Why wont Gilead and the FDA promote research, or allow and encourage others to do so, into Gileads drug GS-441524 that looks superior to Gileads remdesivir drug? (Remdesivir was developed with the FDA and now promoted as a Covid-19 treatment)

Why wont Gilead license GS-441524 (even for animals despite successful animal tests with 100% cure rate for a fatal cat coronavirus) or meaningfully answer questions or allow other third party researchers outside the FDA full access to the information and files to do Covid-19 research on GS-441524?

The info has been updated in the link below

 
Last edited:

adam

BANNED
Jul 2, 2020
183
30
730
Visit site
Why does it take a citizens advocacy group to get the FDA to do the right thing and investigate GS-441524

The FDA have now

“reviewed the literature and agree that this compound merits further exploration,”

This info has been around for a long time


“We are planning to independently test the therapeutic hypothesis for GS-441524 in treating SARS-CoV-2, [which causes Covid-19], and have informed our colleagues at [the National Institute of Allergy and Infectious Diseases] about our plans for preclinical studies. We expect to conduct these studies quickly and make the results available to the research community for further consideration,” the agency said in the letter

Researchers are still seeking permission from Gilead to use data on the compound that is on file with the FDA.




Below is a link to the updated story

 
Last edited:

adam

BANNED
Jul 2, 2020
183
30
730
Visit site
Some say Gilead has blocked research into a potentially much cheaper and better Covid-19 treatment that Gilead also has patent rights over for financial reasons

The FDA has just accepted that the longstanding research shows the drug merits further investigation as a Covid-19 treatment and will begin to do do

The updated info is in the link immediately below


Decide for yourself


Gilead has declined to comment on The Atlantic story which is partly about

the amazing cure GS-441524 has been for a near 100% fatal coronavirus in cats and partly about

Gilead blocking research and licensing the manufacture and use of GS-441524 in cats and people as a treatment for Covid-19 and other coronaviruses.

 
Last edited:

adam

BANNED
Jul 2, 2020
183
30
730
Visit site
Thank you so much for the information keep suggesting us such informative post i will recommend this post to others ACES ETM

Thank you.

There are separate posts on other drugs which show good results against Covid-19

Also a post that compares GS-441524 research to another similar drug that only had about a 35% coronavirus cure rate GC-376 - GC-376 is owned by another company and also never approved for human or animal use

However GC-376 months ago finished Covid-19 University trials with an application for speedy human trials in Canada and the USA expected to be granted shortly partly based on studies showing a 35% cure rate of coronavirus in cats

Both drugs had been researched and tested by UC Davies over some years with GS-441524 having a near 100% cure rate and being used unofficially extensively to cure pet cats

See links below





Another separate post links to press statements made by Gilead from 2019 saying they wont allow use, development or research of GS-441524 in humans or animals until after Remdesivir has been approved by the FDA.



As of early August 2020 nothing had been done and no real updates have been released on how Gilead will cooperate with other researchers on GS-441524


This NIH link on GS-441524 below worked for a short while in October then stopped. Might be a temporary problem. It detailed data about studies of GS-441524


The search originally came up with the data below

NCATS is conducting studies to assess the oral bioavailability of GS-441524 as a potential treatment for SARS-CoV2 infection. Sample Information. Sample Name. GS-441524. NCATS ID. NCGC00686670-1. PubChem SID. 44468216. Molecular Weight. 291.26.

Also unclear if the study below for remdesivir+ is for GS-441524 or remdesivir


There are also updates after the date of the the post you replied to which details issues connected to Gilead - a current legal case in the USA where Gilead is accused by 18,000 people in court filings of withholding a better safer drug for 15 years so as to have a replacement drug in the future.

The legal case claim is Gilead withheld the better drug patent so as not to compete with a much more toxic drug. Both drugs were developed at the same time. Gilead all the time had the test data showing which drug was safer and how the more toxic released drug caused harm and even death. Once the more toxic drug patent expired 15 years later - Gilead then released the safer drug as a new safer version of the previous treatment. Gilead is accused of putting profit over safety and health.

 
Last edited: